143.35
-1.11 (-0.77%)
| Previous Close | 144.46 |
| Open | 142.00 |
| Volume | 333,834 |
| Avg. Volume (3M) | 164,944 |
| Market Cap | 5,746,198,016 |
| Price / Earnings (Forward) | 227.27 |
| Price / Book | 7.29 |
| 52 Weeks Range | |
| Earnings Date | 10 Aug 2026 |
| Diluted EPS (TTM) | -1.36 |
| Total Debt/Equity (MRQ) | 0.37% |
| Current Ratio (MRQ) | 25.98 |
| Operating Cash Flow (TTM) | -29.23 M |
| Levered Free Cash Flow (TTM) | -13.42 M |
| Return on Assets (TTM) | -22.23% |
| Return on Equity (TTM) | -33.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Belite Bio, Inc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 53.93% |
| % Held by Institutions | 0.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 31 Mar 2026 | 3,057,412 |
| Eventide Asset Management, Llc | 31 Mar 2026 | 357,650 |
| Patient Square Capital Lp | 31 Mar 2026 | 116,684 |
| Duquesne Family Office Llc | 31 Mar 2026 | 106,100 |
| Mpm Bioimpact Llc | 31 Mar 2026 | 88,045 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |